Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Reviews
You have accessRestricted Access

Management of Heart Failure Patient with CKD

Debasish Banerjee, Giuseppe Rosano and Charles A. Herzog
CJASN July 2021, 16 (7) 1131-1139; DOI: https://doi.org/10.2215/CJN.14180920
Debasish Banerjee
1Renal and Transplantation Unit, St George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
2Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St Georges, University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Debasish Banerjee
Giuseppe Rosano
2Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St Georges, University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A. Herzog
3Cardiology Division, Department of Internal Medicine, Hennepin Healthcare/University of Minnesota, Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

CKD is common in patients with heart failure, associated with high mortality and morbidity, which is even higher in people undergoing long-term dialysis. Despite increasing use of evidence-based drug and device therapy in patients with heart failure in the general population, patients with CKD have not benefitted. This review discusses prevalence and evidence of kidney replacement, device, and drug therapies for heart failure in CKD. Evidence for treatment with β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and sodium-glucose cotransporter inhibitors in mild-to-moderate CKD has emerged from general population studies in patients with heart failure with reduced ejection fraction (HFrEF). β-Blockers have been shown to improve outcomes in patients with HFrEF in all stages of CKD, including patients on dialysis. However, studies of HFrEF selected patients with creatinine <2.5 mg/dl for ACE inhibitors, <3.0 mg/dl for angiotensin-receptor blockers, and <2.5 mg/dl for mineralocorticoid receptor antagonists, excluding patients with severe CKD. Angiotensin receptor neprilysin inhibitor therapy was successfully used in randomized trials in patients with eGFR as low as 20 ml/min per 1.73 m2. Hence, the benefits of renin-angiotensin-aldosterone axis inhibitor therapy in patients with mild-to-moderate CKD have been demonstrated, yet such therapy is not used in all suitable patients because of fear of hyperkalemia and worsening kidney function. Sodium-glucose cotransporter inhibitor therapy improved mortality and hospitalization in patients with HFrEF and CKD stages 3 and 4 (eGFR>20 ml/min per 1.73 m2). High-dose and combination diuretic therapy, often necessary, may be complicated with worsening kidney function and electrolyte imbalances, but has been used successfully in patients with CKD stages 3 and 4. Intravenous iron improved symptoms in patients with heart failure and CKD stage 3; and high-dose iron reduced heart failure hospitalizations by 44% in patients on dialysis. Cardiac resynchronization therapy reduced death and hospitalizations in patients with heart failure and CKD stage 3. Peritoneal dialysis in patients with symptomatic fluid overload improved symptoms and prevented hospital admissions. Evidence suggests that combined cardiology-nephrology clinics may help improve management of patients with HFrEF and CKD. A multidisciplinary approach may be necessary for implementation of evidence-based therapy.

  • chronic kidney disease
  • heart failure
  • dialysis

Epidemiology of CKD in Heart Failure

Patients with heart failure frequently suffer from coexisting CKD (1). A large meta-analysis suggests that approximately half (49%) of patients with heart failure suffer from CKD (excluding registry studies) (2). The incidence of heart failure in patients with CKD was 18/1000 person-years in a large population-based study in the United States (3). Prevalence of heart failure is higher with decreasing kidney function, and approximately 44% of patients on dialysis suffer from heart failure, and half of these have reduced ejection fraction (1). The prognosis of patients with heart failure and CKD is poor, and worsens with deteriorating kidney function, with a higher mortality (odds ratio, 2.34; 95% confidence interval [95% CI], 2.20 to 2.50; P<0.001) (4). The coexisting CKD is usually caused by diabetes, hypertension, or ischemic kidney disease (see case in Box 1). Consider a 54-year-old man with diabetes, hypertension, and heart failure owing to severe coronary artery disease who presents with fluid overload and near ESKD. In patients like this, prognosis is poor and management is difficult. Patients with CKD were older in most studies, which may be because of age-related decline in GFR; however, presence of CKD was associated with higher mortality when adjusted for age (5). In addition, a significant number of patients with heart failure also suffer from AKI resulting from a variety of conditions, such as sepsis, kidney hypoperfusion, and drug toxicity, with significant adverse outcomes (6). However, the worsening of eGFR because of initiation of renin-angiotensin-aldosterone system inhibitors (RAASis) does not bear the same long-term consequences as persistent AKI owing to sepsis or hypovolemia (7,8).

View this table:
  • View inline
  • View popup
Box 1.

Case discussion

The Interdependence of the Heart and Kidney

The heart and the kidney are interlinked in physiologic states to maintain salt-water homeostasis and normal BP. In health, the crosstalk between the two organs helps the body to respond to changes in kidney perfusion resulting from volume depletion or overload, to maintain appropriate blood flow to vital organs and thereby avoid ischemia or hyperperfusion injury. In disease, the kidney and heart can adversely affect each other’s function (9). On the one hand, inability to excrete salt and water and abnormal renin secretion by the diseased kidney increases cardiac preload, afterload, and heart failure; on the other hand, poor kidney perfusion owing to low cardiac output, and renal venous congestion owing to right heart failure, causes kidney failure. When both organs are diseased, they adversely affect each other’s function, which poses significant challenges in the management of patients with compromised heart and kidney function. Common pathologic mechanisms may affect both organs and cause simultaneous dysfunction of the kidney and heart (10).

The neurohumoral interactions between the two organs are complex in disease states. The natriuretic peptides, which induce diuresis with cardiac volume overload, are upregulated with kidney disease so as to help with associated fluid retention; however, they can be elevated because of poor elimination of the peptide molecules by the kidneys themselves. During treatment of heart failure with diuretics, although congestive symptoms and brain natriuretic peptide (BNP) concentrations improve, kidney function may worsen because of a reduction in kidney plasma flow (11). Stopping of diuretics may improve kidney function but worsen cardiac volumes and levels of BNP.

In heart failure with reduced ejection fraction (HFrEF), the renin, angiotensin, and aldosterone levels increase with hypotension, in response to low kidney perfusion, to improve GFR by efferent arteriolar vasoconstriction and increase systemic BP. However, the excess fluid retention caused by increased levels of renin, angiotensin, and aldosterone may increase the volume overload of the heart and cause further deterioration of heart failure.

Treatment with angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs) lowers intraglomerular pressure caused by efferent arteriolar vasodilation, presenting as apparent worsening of kidney function, which causes anxiety in treating physicians. However, with ACEis, eGFR decline up to 35% has been associated with improved heart failure hospitalization rates (12).

Progression of CKD in patients with heart failure is perhaps faster than in patients without heart failure in the absence of AKI; for example, in the recently completed EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR)-reduced trial, eGFR declined by 4.2 ml/min per 1.73 m2 (95% CI, 3.1 to 5.3) in the placebo arm, over a median follow-up of 16 months, with most patients on ACEis and a baseline eGFR of 62±21 ml/min per 1.73 m2 (13).

AKI in Patients with Heart Failure and CKD

The incidence of AKI is high in patients with heart failure. Incidence of AKI among acute heart failure admissions at St George’s Hospital was 17% in 1094 patients admitted with acute decompensated heart failure, and inpatient mortality was 21% with stage 1, 36% with stage 2, and 48% with stage 3 AKI (P<0.001) (6). In a meta-analysis of 28 trials with 49,890 patients, the incidence of AKI or worsening of kidney function was 23%, and the mortality was higher (odds ratio, 1.81; 95% CI, 1.55 to 2.12; P<0.001) over 488±569 days (2). In a unique situation in cardiology, when the kidney insult is known and preventive measures are used (i.e., with coronary angiogram), the incidence was 7.1% in 985,737 US patients undergoing percutaneous coronary interventions, and was higher with the presence of CKD and heart failure (14). The other causes of AKI in patients with heart failure are infection, sepsis, volume depletion, drug toxicity, and obstruction of the urinary tract in older men with enlarged prostate.

Certain classes of drugs decrease kidney function at therapy initiation, which is distinguished from true AKI by the term “permissive AKI,” or “hemodynamic AKI.” ACEis and ARBs work by dilating the efferent arteriole, thereby lowering intraglomerular pressure and preventing long-term harmful effects of hyperfiltration in individual nephrons (e.g., glomerulosclerosis) in patients with CKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recently introduced class of oral hypoglycemics, cause a drop in eGFR at therapy initiation. With canagliflozin, a SGLT2i in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial (CREDENCE) study (baseline eGFR of 56 ml/min per 1.73 m2), the initial drop of eGFR was followed by a slowing of progression of CKD and improvement in heart failure outcomes. The drop in eGFR at 3 weeks in the canagliflozin arm was 3.17 ml/min per 1.73 m2 (95% CI, 3.87 to 2.47) more than in the placebo arm, yet the decline in eGFR was less over longer follow-up (15). The drop in eGFR in the first 4 weeks was similar with empagliflozin in the EMPEROR-reduced trial, where the baseline eGFR was 62±22 ml/min per 1.73 m2 (13). The initial worsening of GFR is likely a result of increased delivery of salt and water to the distal tubule, which, in turn, decreases glomerular filtration pressure through the crosstalk between the distal tubule and efferent arteriole of the same nephron by a mechanism known as “tubuloglomerular feedback.”

Heart Failure Therapy in Patients with CKD

Management of chronic heart failure in the general population has changed over the past 3 decades. Novel agents such as ivabradine, angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor inhibitors, and cardiac resynchronization therapy have improved survival. Many trials have included patients with mild-to-moderate CKD, and evidence has emerged for newer agents in the treatment of patients with heart failure and CKD, which is discussed below, and summarized in Figure 1 and Table 1 (1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The figure shows level of evidence for heart failure management in patients with CKD with different levels of kidney function. Adapted from the Kidney Disease Improving Global Outcomes Consensus Conference report (1). The increasing levels of evidence for improved outcomes (mortality and hospitalizations) are shown for each therapy on the y axis, with increasing levels of GFR on the x axis. Evidence is strong for BBs, ACEis, ARBs, and MRAs and moderate for CRTs and ivabradine for eGFR>30 ml/min per 1.73 m2. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; CKD G3a–3b, chronic kidney disease grade 3a and 3b; CKD G4, chronic kidney disease grade 4; CKD G5D, chronic kidney disease GFR category 5 patient on dialysis; CKD G5 ND, chronic kidney disease GFR category 5 patient not on dialysis; CRT, cardiac resynchronization therapy; EF, ejection fraction; H-ISDN, hydralazine-isosorbide dinitrate; ICD, implantable cardioverter defibrillator; IV, intravenous; LBBB, left bundle branch block; MRA, mineralocorticoid receptor antagonist; PO, oral; QRS, QRS wave length in electrocardiogram.

View this table:
  • View inline
  • View popup
Table 1.

Heart failure studies in general population with clinical characteristics including creatinine- or eGFR-based inclusion criterion

Diuretic Therapy

As seen in the case in Box 1, water retention and lung congestion in patients with heart failure and CKD causes breathlessness, poor exercise tolerance, and multiple hospital admissions, resulting in poor quality of life. Diuretic therapy is challenging in these patients because of the need for higher doses, frequently causing transient worsening kidney function and electrolyte imbalances such as hyponatremia and hypokalemia (16). These challenges result in the patient needing to visit a variety of specialty doctors, each changing diuretic agents and diuretic doses, often to minimize adverse electrolyte and creatinine changes, and resulting in poor symptom control for the volume-overloaded patient. Renal venous congestion and consequent kidney dysfunction owing to elevated right heart pressure is an often mentioned, poorly understood, and difficult to manage condition, requiring careful escalation of diuretic doses with close monitoring of weight, electrolytes, and creatinine (17). With appropriate use of diuretic therapy, working on different segments of the nephron, symptoms can be controlled and survival may be better. Commonly used thiazide diuretics may not be effective, and loop diuretics are often used with metolazone, as necessary. Intravenous diuretics are used for admitted patients with acute decompensated heart failure. However, there is no significant difference between continuous infusion or bolus administration of intravenous diuretics (16). Spironolactone in patients with acute heart failure can be natriuretic and relieve congestion without significant adverse effect on serum potassium levels (18). A study by the National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network has demonstrated that in 360 patients with acute heart failure and CKD stages 3 and 4, rapid diuresis of 8425 ml (interquartile range 6341–10,528) over 72 hours, with 560 mg (interquartile range 300–815) of furosemide, was safe and was not associated with elevation of markers of tubular injury despite some worsening of creatinine (19). Aggressive diuresis may be useful, provided that the patient is adequately decongested, as evidenced by improvement of physical symptoms and decreased BNP and hemoconcentration, despite the rise in creatinine (20).

Renin-Angiotensin-Aldosterone System Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD

Randomized controlled trials have shown improvement of survival in patients with heart failure with use of ACEis (or ARBs) and mineralocorticoid receptor antagonists. Most of these studies included patients with mild-to-moderate (i.e., stages 1–3) CKD (21). Patients with severe CKD have been excluded from most ACEi studies (Figure 1, Tables 1 and 2).

View this table:
  • View inline
  • View popup
Table 2.

Pharmacotherapy of heart failure in patients with CKD

Mineralocorticoid receptor antagonist therapy has been associated with improved survival of patients with symptomatic heart failure; in a randomized controlled trial of spironolactone, 50% of patients had a GFR of <60 ml/min per 1.73 m2, hence the benefits of the trial extended in CKD patients. Similarly, eplerenone was beneficial in patients with postmyocardial infarction heart failure and CKD. However, hyperkalemia was not infrequent and was associated with discontinuation of the therapy.

The use of ACEis and mineralocorticoid receptor antagonists, particularly in patients with CKD, is often associated with hyperkalemia and rising creatinine. Rising creatinine of up to 40% has been observed in ACEi trials, without significant effects on long-term outcomes (12,22). A rise of up to 30% can be viewed as resulting from hemodynamic changes owing to RAASis (23). In fact, such a change may be beneficial and is named permissive AKI as opposed to true AKI due to other reasons in patients with HFrEF, which requires careful history taking and physical examination (7). RAASis should be stopped when kidney blood flow autoregulation is necessary in the patient, e.g., with diarrhea causing volume depletion.

Patients are referred back and forth, between nephrologists and cardiologists, with RAASi-induced changes in creatinine and potassium, resulting in multiple hospital attendances and, often, discontinuation of the RAASi. Analysis of 194,456 patient records showed increasing frequency of hyperkalemia of up to 30% in patients with CKD stages 4 and 5 if measured more than four times a year, and discontinuation of ACEis/ARBs in 24% of patients (24). Nephrologists traditionally have managed hyperkalemia with judicious use of diuretics and correction of acidosis, but oral potassium binders such as patiromer or sodium zirconium cyclosilicate may be useful (25). Randomized controlled studies of new potassium binders for maximization of RAASi therapy in patients with advanced CKD and heart failure are necessary. A close collaboration between nephrologists and cardiologists is necessary for successful initiation and continuation of RAASi in patients with CKD and heart failure.

Angiotensin Receptor and Neprilysin Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD

A large randomized controlled trial of dual angiotensin receptor and neprilysin inhibitor therapy excluded patients with eGFR<30 ml/min per 1.73 m2 (see Figure 1, Tables 1 and 2), but included patients with only mild CKD (26). A randomized controlled trial of angiotensin receptor neprilysin inhibitors, including patients with eGFR as low as 20 ml/min per 1.73 m2, demonstrated safety and efficacy similar to irbesartan (27). More recently, angiotensin receptor and neprilysin inhibitor therapy has been shown to slow the progression of CKD in patients with heart failure with preserved ejection fraction (HFpEF) more effectively than valsartan (28). The recommended starting dosage for patients with eGFR<60 ml/min per 1.73 m2 is 24 mg sacubitril and 26 mg valsartan, administered twice per day, at least 36 hours after stopping ACEis or ARBs; the dose is then increased, with careful monitoring of creatinine, potassium, and BP.

Ivabradine and β-Blocker Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD

β-Blockers are beneficial in patients with HFrEF and CKD, as evidenced in studies of CKD and the general population (Figures 1 and 2, Tables 1 and 2) (29⇓⇓⇓–33). Carvedilol has been shown to be beneficial in patients with heart failure with CKD stage 5 who are receiving dialysis (34).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The figure shows m anagement strategy for patients with heart failure and CKD, including KRT. Adapted from the Kidney Disease Improving Global Outcomes Consensus Conference report (1). Stepwise, evidence-based drug therapy (increasing levels of evidence from the top to bottom of the pyramid) is shown in the middle. The bars on either side of the pyramid show relevant supportive treatment. AF, atrial fibrillation; ARNI, angiotensin receptor neprilysin inhibitor; CKD-MBD, CKD with mineral and bone disorder; CRRT, continuous KRT; i.v., intravenous; NSAID, nonsteroidal anti-inflammatory drug; RAASi, renin-angiotensin-aldosterone system inhibitor.

The Ivabradine and outcomes in chronic heart failure (SHIFT) study demonstrated improved hospitalization and deaths owing to heart failure with ivabradine treatment in patients with HFrEF with a heart rate >70 beats per minute despite β-blocker therapy, which included patients with creatinine <2.5 mg/dl. The study included 1589 patients with CKD stage 3, and benefits in patients with CKD were similar to patients without CKD (35). Ivabradine is metabolized by the CYP3A4 enzyme in the liver and gut, and elimination by kidneys is minimal. The dosage is 2.5–7.5 mg twice per day and does not require dose adjustment with creatinine clearance of >15 ml/min.

Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD

SGLT2i therapy in patients with heart failure has been recently shown to reduce mortality and hospitalizations. The recently completed dapagliflozin study included 1926 patients with CKD stage 3 and was able to achieve a risk reduction for composite end points of 28% versus 24% in patients with eGFR>60 ml/min per 1.73 m2 (see Box 1, Table 1). Adverse kidney events with dapagliflozin was not higher compared with placebo (36). More recently, empagliflozin was shown to reduce heart failure hospitalization and eGFR decline, including in patients with eGFR as low as 20 ml/min per 1.73 m2 (48% had eGFR<60 ml/min per 1.73 m2) (13). The Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) trial has reported lower heart failure admissions in patients with CKD (eGFR >25 but <75 ml/min per 1.73 m2) and proteinuria.

Management of Iron Deficiency and Anemia in Patients with Heart Failure with Reduced Ejection Fraction and CKD

Nephrologists have been using intravenous iron for the past 3 decades to treat anemia in patients with CKD, both before and during dialysis. In the United Kingdom, a recent study in patients receiving dialysis has shown benefits of high-dose intravenous iron in reducing mortality and morbidity, together with heart failure hospitalizations by 44% (37). A previous trial of benefits of intravenous iron in patients with HFrEF included patients with early stages of CKD (38). A collaboration between cardiologists and nephrologists may assist the management of iron deficiency in patients with HFrEF and CKD.

KRT

CKD is a progressive disease with declining kidney function over time, causing frequent episodes of fluid overload and hyperkalemia, further complicated by episodes of AKI. With eGFR<20 ml/min per 1.73 m2, decisions need to be made, in discussion with the patient, about indications, appropriateness, and modality of KRT. Careful consideration of patient expectations, comorbidities, frailty, and quality of life are necessary factors to consider when starting KRT. Patients with heart failure on dialysis have very poor prognosis, with a 5-year survival rate of 12.5% (39). There may be symptomatic relief and fewer hospitalizations with peritoneal dialysis in carefully selected patients (40). In a study of 118 patients with heart failure and CKD, peritoneal dialysis was associated with improvement in quality of life and New York Heart Association class (41). A meta-analysis of 23 studies demonstrated benefits of peritoneal dialysis in patients with heart failure and CKD, with improved hospitalization rates and heart function (42). In patients with refractory heart failure, overnight ultrafiltration with icodextrin solution improved quality of life, heart function, and New York Heart Association class (43). Hemodialysis may be tricky in patients with low BP, but more frequent dialysis and longer nocturnal dialysis may be useful for fluid removal. However, creation of arteriovenous fistula or graft for hemodialysis may cause dilation of left atrium and right ventricle, and associated heart failure (44). For patients with acute heart failure and low BP, slow ultrafiltration with continuous KRT may be useful.

Device Therapy

Rate of CKD progression to dialysis, associated blood stream infection, patient’s age, and general health determine the benefits of other treatments, such as use of cardiac resynchronization therapy and implantation of defibrillators. Cardiac synchronization therapy was beneficial in patients with CKD stage 3 in a Canadian study, of which more than half of patients had eGFR<60 ml/min per 1.73 m2 (45). In a meta-analysis of five retrospective studies, defibrillator therapy was associated with improvement in mortality of patients at high risk of sudden cardiac death (46). Defibrillator therapy in dialysis was associated with high infection rates, and a recent randomized trial in patients on hemodialysis has failed to show any significant benefit (47,48).

Heart Failure with Preserved Ejection Fraction in Patients with CKD

The diagnosis of HFpEF in patients with CKD may be challenging. The BNP levels may be elevated because of the CKD and may not be diagnostic. The fluid overload may be a result of CKD itself. These patients have similar risk of poor outcomes and suffer frequent hospital admissions because of fluid overload, similar to patients with heart failure with reduced ejection function (49). Careful use of diuretics is necessary to control the symptoms of volume overload. Nonsteroidal anti-inflammatory drugs should be avoided because they can cause AKI and fluid retention in patients with CKD, and mimic HFpEF. There is no compelling evidence for effective therapy in HFpEF to improve outcomes such as cardiovascular mortality or heart failure hospitalizations. However, large trials are underway, such as FINEARTS-HF (ClinicalTrials.gov identifier NCT04435626) [Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%], a randomized controlled trial of finerenone (a nonsteroidal mineralocorticoid receptor antagonist) in patients with CKD and HFpEF.

Multidisciplinary Care

Patients with CKD and heart failure need multidisciplinary care to minimize the number of health care visits. A close working relationship between nephrologists and cardiologists is the key to controlling symptoms and prolonging life where possible; treating with diuretics, ACEis, and mineralocorticoid receptor antagonists, while avoiding electrolyte abnormalities and AKI; and advising appropriately for dialysis and device therapy (Figure 2) (1). In a recent study in St George’s Hospital, multidisciplinary care was associated with improvement in iron stores and RAASi use in 124 patients with CKD and heart failure (50). A multidisciplinary cardiology-nephrology service with doctors and specialist nurses in the United Kingdom has demonstrated better utilization of evidence-based therapy and health care resources (51). A similar multidisciplinary meeting for prekidney transplant patients, with cardiologists, nephrologists, transplant surgeons, and specialist nurses, showed that high-cardiac-risk patients can be safely transplanted (52).

The Way Forward

To achieve appropriate therapy and the best possible outcome, combined cardiology-nephrology clinics are necessary, as demonstrated by the success of the kidney and heart failure clinic at St George’s Hospital, which manages kidney and heart care, together with intravenous iron and advice on dialysis therapy (50). Patients appreciate the multiple benefits from a single visit and provide excellent feedback. The multidisciplinary “one-stop shop” clinic is very patient centered and helps with decision making regarding RAASi, device therapy, and intravenous iron administration, but requires proper resources, including the presence of a nephrologist, cardiologist, anemia nurse, and appropriate space. However, once economic and outcome benefits of a combined clinic are established, such clinics need to be replicated in other institutions. With improved knowledge among cardiologists and nephrologists, multidisciplinary approach, evidenced-based therapy can be implemented in patients with early-to-moderate CKD. However, we recognize that more studies are necessary to strengthen the evidence base in patients with advanced CKD.

Disclosures

D. Banerjee reports receiving lecture fees from Pfizer and ViforPharma; grants and lecture fees from AstraZeneca; and grants from BHF, KRUK, and Wellcome Trust, outside the submitted work. C.A. Herzog reports receiving honoraria from UpToDate; receiving consultation fees from Abbvie, Amgen, Corvidia, Diamedica, Fibrogen, Janssen, NxStage, Pfizer, Relypsa, Sanifit, and University of Oxford; receiving grants from Amgen, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Relapsa, and University of British Columbia; being a stockholder of Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson & Johnson, and Merck; and being an employee of Hennepin Healthcare, outside the submitted work. The remaining author has nothing to disclose.

Funding

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. House AA,
    2. Wanner C,
    3. Sarnak MJ,
    4. Piña IL,
    5. McIntyre CW,
    6. Komenda P,
    7. Kasiske BL,
    8. Deswal A,
    9. deFilippi CR,
    10. Cleland JGF,
    11. Anker SD,
    12. Herzog CA,
    13. Cheung M,
    14. Wheeler DC,
    15. Winkelmayer WC,
    16. McCullough PA
    ; Conference Participants: Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95: 1304–1317, 2019pmid:31053387
    OpenUrlPubMed
  2. ↵
    1. Damman K,
    2. Valente MA,
    3. Voors AA,
    4. O’Connor CM,
    5. van Veldhuisen DJ,
    6. Hillege HL
    : Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 35: 455–469, 2014pmid:24164864
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kottgen A,
    2. Russell SD,
    3. Loehr LR,
    4. Crainiceanu CM,
    5. Rosamond WD,
    6. Chang PP,
    7. Chambless LE,
    8. Coresh J
    : Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 18: 1307–1315, 2007 pmid:17344421
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Damman K,
    2. Testani JM
    : The kidney in heart failure: An update. Eur Heart J 36: 1437–1444, 2015pmid:25838436
    OpenUrlCrossRefPubMed
  5. ↵
    1. Amsalem Y,
    2. Garty M,
    3. Schwartz R,
    4. Sandach A,
    5. Behar S,
    6. Caspi A,
    7. Gottlieb S,
    8. Ezra D,
    9. Lewis BS,
    10. Leor J
    : Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. Eur Heart J 29: 1029–1036, 2008pmid:18339607
    OpenUrlCrossRefPubMed
  6. ↵
    1. Jenkins R,
    2. Mandarano L,
    3. Gugathas S,
    4. Kaski JC,
    5. Anderson L,
    6. Banerjee D
    : Impaired renal function affects clinical outcomes and management of patients with heart failure. ESC Heart Fail 4: 576–584, 2017pmid:28872780
    OpenUrlPubMed
  7. ↵
    1. Testani JM,
    2. Kimmel SE,
    3. Dries DL,
    4. Coca SG
    : Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4: 685–691, 2011pmid:21903907
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Krishnamoorthy A,
    2. Greiner MA,
    3. Sharma PP,
    4. DeVore AD,
    5. Johnson KW,
    6. Fonarow GC,
    7. Curtis LH,
    8. Hernandez AF
    : Transient and persistent worsening renal function during hospitalization for acute heart failure. Am Heart J 168: 891–900, 2014pmid:25458653
    OpenUrlPubMed
  9. ↵
    1. Ronco C,
    2. Haapio M,
    3. House AA,
    4. Anavekar N,
    5. Bellomo R
    : Cardiorenal syndrome. J Am Coll Cardiol 52: 1527–1539, 2008pmid:19007588
    OpenUrlFREE Full Text
  10. ↵
    1. Zannad F,
    2. Rossignol P
    : Cardiorenal syndrome revisited. Circulation 138: 929–944, 2018pmid:30354446
    OpenUrlPubMed
  11. ↵
    1. Brisco MA,
    2. Zile MR,
    3. Hanberg JS,
    4. Wilson FP,
    5. Parikh CR,
    6. Coca SG,
    7. Tang WH,
    8. Testani JM
    : Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: Insights from the DOSE trial. J Card Fail 22: 753–760, 2016pmid:27374839
    OpenUrlPubMed
  12. ↵
    1. McCallum W,
    2. Tighiouart H,
    3. Ku E,
    4. Salem D,
    5. Sarnak MJ
    : Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Kidney Int 96: 1185–1194, 2019pmid:31420191
    OpenUrlPubMed
  13. ↵
    1. Packer M,
    2. Anker SD,
    3. Butler J,
    4. Filippatos G,
    5. Pocock SJ,
    6. Carson P,
    7. Januzzi J,
    8. Verma S,
    9. Tsutsui H,
    10. Brueckmann M,
    11. Jamal W,
    12. Kimura K,
    13. Schnee J,
    14. Zeller C,
    15. Cotton D,
    16. Bocchi E,
    17. Böhm M,
    18. Choi DJ,
    19. Chopra V,
    20. Chuquiure E,
    21. Giannetti N,
    22. Janssens S,
    23. Zhang J,
    24. Gonzalez Juanatey JR,
    25. Kaul S,
    26. Brunner-La Rocca HP,
    27. Merkely B,
    28. Nicholls SJ,
    29. Perrone S,
    30. Pina I,
    31. Ponikowski P,
    32. Sattar N,
    33. Senni M,
    34. Seronde MF,
    35. Spinar J,
    36. Squire I,
    37. Taddei S,
    38. Wanner C,
    39. Zannad F
    ; EMPEROR-Reduced Trial Investigators: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383: 1413–1424, 2020pmid:32865377
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tsai TT,
    2. Patel UD,
    3. Chang TI,
    4. Kennedy KF,
    5. Masoudi FA,
    6. Matheny ME,
    7. Kosiborod M,
    8. Amin AP,
    9. Messenger JC,
    10. Rumsfeld JS,
    11. Spertus JA
    : Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 7: 1–9, 2014pmid:24456715
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Perkovic V,
    2. Jardine MJ,
    3. Neal B,
    4. Bompoint S,
    5. Heerspink HJL,
    6. Charytan DM,
    7. Edwards R,
    8. Agarwal R,
    9. Bakris G,
    10. Bull S,
    11. Cannon CP,
    12. Capuano G,
    13. Chu PL,
    14. de Zeeuw D,
    15. Greene T,
    16. Levin A,
    17. Pollock C,
    18. Wheeler DC,
    19. Yavin Y,
    20. Zhang H,
    21. Zinman B,
    22. Meininger G,
    23. Brenner BM,
    24. Mahaffey KW
    ; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019pmid:30990260
    OpenUrlCrossRefPubMed
  16. ↵
    1. Felker GM,
    2. Lee KL,
    3. Bull DA,
    4. Redfield MM,
    5. Stevenson LW,
    6. Goldsmith SR,
    7. LeWinter MM,
    8. Deswal A,
    9. Rouleau JL,
    10. Ofili EO,
    11. Anstrom KJ,
    12. Hernandez AF,
    13. McNulty SE,
    14. Velazquez EJ,
    15. Kfoury AG,
    16. Chen HH,
    17. Givertz MM,
    18. Semigran MJ,
    19. Bart BA,
    20. Mascette AM,
    21. Braunwald E,
    22. O’Connor CM
    ; NHLBI Heart Failure Clinical Research Network: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364: 797–805, 2011pmid:21366472
    OpenUrlCrossRefPubMed
  17. ↵
    1. Testani JM,
    2. Damman K
    : Venous congestion and renal function in heart failure ... it’s complicated. Eur J Heart Fail 15: 599–601, 2013pmid:23603089
    OpenUrlCrossRefPubMed
  18. ↵
    1. Verbrugge FH,
    2. Martens P,
    3. Ameloot K,
    4. Haemels V,
    5. Penders J,
    6. Dupont M,
    7. Tang WHW,
    8. Droogné W,
    9. Mullens W
    : Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol 74: 100–107, 2019pmid:29587582
    OpenUrlPubMed
  19. ↵
    1. Ahmad T,
    2. Jackson K,
    3. Rao VS,
    4. Tang WHW,
    5. Brisco-Bacik MA,
    6. Chen HH,
    7. Felker GM,
    8. Hernandez AF,
    9. O’Connor CM,
    10. Sabbisetti VS,
    11. Bonventre JV,
    12. Wilson FP,
    13. Coca SG,
    14. Testani JM
    : Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 137: 2016–2028, 2018pmid:29352071
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Yamada T,
    2. Ueyama H,
    3. Chopra N,
    4. Yamaji T,
    5. Azushima K,
    6. Kobayashi R,
    7. Kinguchi S,
    8. Urate S,
    9. Suzuki T,
    10. Abe E,
    11. Saigusa Y,
    12. Wakui H,
    13. Partridge P,
    14. Burger A,
    15. Bravo CA,
    16. Rodriguez MA,
    17. Ivey-Miranda J,
    18. Tamura K,
    19. Testani J,
    20. Coca S
    : Systematic review of the association between worsening renal function and mortality in patients with acute decompensated heart failure. Kidney Int Rep 5: 1486–1494, 2020pmid:32954072
    OpenUrlPubMed
  21. ↵
    1. Bowling CB,
    2. Sanders PW,
    3. Allman RM,
    4. Rogers WJ,
    5. Patel K,
    6. Aban IB,
    7. Rich MW,
    8. Pitt B,
    9. White M,
    10. Bakris GC,
    11. Fonarow GC,
    12. Ahmed A
    : Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial. Int J Cardiol 167: 151–156, 2013pmid:22257685
    OpenUrlCrossRefPubMed
  22. ↵
    1. McCallum W,
    2. Tighiouart H,
    3. Ku E,
    4. Salem D,
    5. Sarnak MJ
    : Trends in kidney function outcomes following RAAS inhibition in patients with heart failure with reduced ejection fraction. Am J Kidney Dis 75: 21–29, 2020pmid:31303349
    OpenUrlPubMed
  23. ↵
    1. Clark AL,
    2. Kalra PR,
    3. Petrie MC,
    4. Mark PB,
    5. Tomlinson LA,
    6. Tomson CR
    : Change in renal function associated with drug treatment in heart failure: National guidance. Heart 105: 904–910, 2019pmid:31118203
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Chang AR,
    2. Sang Y,
    3. Leddy J,
    4. Yahya T,
    5. Kirchner HL,
    6. Inker LA,
    7. Matsushita K,
    8. Ballew SH,
    9. Coresh J,
    10. Grams ME
    : Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67: 1181–1188, 2016pmid:27067721
    OpenUrlCrossRefPubMed
  25. ↵
    1. Pitt B,
    2. Bushinsky DA,
    3. Kitzman DW,
    4. Ruschitzka F,
    5. Metra M,
    6. Filippatos G,
    7. Rossignol P,
    8. Du Mond C,
    9. Garza D,
    10. Berman L,
    11. Lainscak M
    ; Patiromer-204 Investigators: Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 5: 257–266, 2018
    OpenUrl
  26. ↵
    1. McMurray JJ,
    2. Packer M,
    3. Desai AS,
    4. Gong J,
    5. Lefkowitz MP,
    6. Rizkala AR,
    7. Rouleau JL,
    8. Shi VC,
    9. Solomon SD,
    10. Swedberg K,
    11. Zile MR
    ; PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993–1004, 2014pmid:25176015
    OpenUrlCrossRefPubMed
  27. ↵
    1. Haynes R,
    2. Judge PK,
    3. Staplin N,
    4. Herrington WG,
    5. Storey BC,
    6. Bethel A,
    7. Bowman L,
    8. Brunskill N,
    9. Cockwell P,
    10. Hill M,
    11. Kalra PA,
    12. McMurray JJV,
    13. Taal M,
    14. Wheeler DC,
    15. Landray MJ,
    16. Baigent C
    : Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138: 1505–1514, 2018pmid:30002098
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Mc Causland FR,
    2. Lefkowitz MP,
    3. Claggett B,
    4. Anavekar NS,
    5. Senni M,
    6. Gori M,
    7. Jhund PS,
    8. McGrath MM,
    9. Packer M,
    10. Shi V,
    11. Van Veldhuisen DJ,
    12. Zannad F,
    13. Comin-Colet J,
    14. Pfeffer MA,
    15. McMurray JJV,
    16. Solomon SD
    : Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142: 1236–1245, 2020pmid:32845715
    OpenUrlPubMed
  29. ↵
    MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001–2007, 1999pmid:10376614
    OpenUrlCrossRefPubMed
  30. ↵
    1. CIBIS-II Investigators and Committees
    : The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353: 9–13, 1999 10023943
  31. ↵
    1. Packer M,
    2. Coats AJ,
    3. Fowler MB,
    4. Katus HA,
    5. Krum H,
    6. Mohacsi P,
    7. Rouleau JL,
    8. Tendera M,
    9. Castaigne A,
    10. Roecker EB,
    11. Schultz MK,
    12. DeMets DL
    ; Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658, 2001pmid:11386263
    OpenUrlCrossRefPubMed
  32. ↵
    1. Flather MD,
    2. Shibata MC,
    3. Coats AJ,
    4. Van Veldhuisen DJ,
    5. Parkhomenko A,
    6. Borbola J,
    7. Cohen-Solal A,
    8. Dumitrascu D,
    9. Ferrari R,
    10. Lechat P,
    11. Soler-Soler J,
    12. Tavazzi L,
    13. Spinarova L,
    14. Toman J,
    15. Böhm M,
    16. Anker SD,
    17. Thompson SG,
    18. Poole-Wilson PA
    ; SENIORS Investigators: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225, 2005pmid:15642700
    OpenUrlCrossRefPubMed
  33. ↵
    1. Lunney M,
    2. Ruospo M,
    3. Natale P,
    4. Quinn RR,
    5. Ronksley PE,
    6. Konstantinidis I,
    7. Palmer SC,
    8. Tonelli M,
    9. Strippoli G,
    10. Ravani P
    : Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database Syst Rev 2: CD012466, 2020
    OpenUrl
  34. ↵
    1. Cice G,
    2. Ferrara L,
    3. D’Andrea A,
    4. D’Isa S,
    5. Di Benedetto A,
    6. Cittadini A,
    7. Russo PE,
    8. Golino P,
    9. Calabrò R
    : Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 41: 1438–1444, 2003pmid:12742278
    OpenUrlFREE Full Text
  35. ↵
    1. Voors AA,
    2. van Veldhuisen DJ,
    3. Robertson M,
    4. Ford I,
    5. Borer JS,
    6. Böhm M,
    7. Komajda M,
    8. Swedberg K,
    9. Tavazzi L
    ; SHIFT Investigators: The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT. Eur J Heart Fail 16: 426–434, 2014pmid:24504937
    OpenUrlCrossRefPubMed
  36. ↵
    1. McMurray JJV,
    2. Solomon SD,
    3. Inzucchi SE,
    4. Køber L,
    5. Kosiborod MN,
    6. Martinez FA,
    7. Ponikowski P,
    8. Sabatine MS,
    9. Anand IS,
    10. Bělohlávek J,
    11. Böhm M,
    12. Chiang CE,
    13. Chopra VK,
    14. de Boer RA,
    15. Desai AS,
    16. Diez M,
    17. Drozdz J,
    18. Dukát A,
    19. Ge J,
    20. Howlett JG,
    21. Katova T,
    22. Kitakaze M,
    23. Ljungman CEA,
    24. Merkely B,
    25. Nicolau JC,
    26. O’Meara E,
    27. Petrie MC,
    28. Vinh PN,
    29. Schou M,
    30. Tereshchenko S,
    31. Verma S,
    32. Held C,
    33. DeMets DL,
    34. Docherty KF,
    35. Jhund PS,
    36. Bengtsson O,
    37. Sjöstrand M,
    38. Langkilde AM
    ; DAPA-HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995–2008, 2019pmid:31535829
    OpenUrlCrossRefPubMed
  37. ↵
    1. Macdougall IC,
    2. White C,
    3. Anker SD,
    4. Bhandari S,
    5. Farrington K,
    6. Kalra PA,
    7. McMurray JJV,
    8. Murray H,
    9. Tomson CRV,
    10. Wheeler DC,
    11. Winearls CG,
    12. Ford I
    ; PIVOTAL Investigators and Committees: Intravenous iron in patients undergoing maintenance hemodialysis [published correction appears in N Engl J Med 380: 502, 2019 10.1056/NEJMx180044]. N Engl J Med 380: 447–458, 2019pmid:30365356
    OpenUrlCrossRefPubMed
  38. ↵
    1. Anker SD,
    2. Comin Colet J,
    3. Filippatos G,
    4. Willenheimer R,
    5. Dickstein K,
    6. Drexler H,
    7. Lüscher TF,
    8. Bart B,
    9. Banasiak W,
    10. Niegowska J,
    11. Kirwan BA,
    12. Mori C,
    13. von Eisenhart Rothe B,
    14. Pocock SJ,
    15. Poole-Wilson PA,
    16. Ponikowski P
    ; FAIR-HF Trial Investigators: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436–2448, 2009pmid:19920054
    OpenUrlCrossRefPubMed
  39. ↵
    1. Banerjee D,
    2. Ma JZ,
    3. Collins AJ,
    4. Herzog CA
    : Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2: 1186–1190, 2007pmid:17942779
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Núñez J,
    2. González M,
    3. Miñana G,
    4. Garcia-Ramón R,
    5. Sanchis J,
    6. Bodí V,
    7. Núñez E,
    8. Puchades MJ,
    9. Palau P,
    10. Merlos P,
    11. Llàcer A,
    12. Miguel A
    : Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14: 540–548, 2012pmid:22327061
    OpenUrlCrossRefPubMed
  41. ↵
    1. Koch M,
    2. Haastert B,
    3. Kohnle M,
    4. Rump LC,
    5. Kelm M,
    6. Trapp R,
    7. Aker S
    : Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 14: 530–539, 2012pmid:22447950
    OpenUrlCrossRefPubMed
  42. ↵
    1. Lu R,
    2. Muciño-Bermejo MJ,
    3. Ribeiro LC,
    4. Tonini E,
    5. Estremadoyro C,
    6. Samoni S,
    7. Sharma A,
    8. Zaragoza Galván JJ,
    9. Crepaldi C,
    10. Brendolan A,
    11. Ni Z,
    12. Rosner MH,
    13. Ronco C
    : Peritoneal dialysis in patients with refractory congestive heart failure: A systematic review. Cardiorenal Med 5: 145–156, 2015pmid:25999963
    OpenUrlCrossRefPubMed
  43. ↵
    1. Wojtaszek E,
    2. Grzejszczak A,
    3. Niemczyk S,
    4. Malyszko J,
    5. Matuszkiewicz-Rowińska J
    : Peritoneal ultrafiltration in the long-term treatment of chronic heart failure refractory to pharmacological therapy. Front Physiol 10: 310, 2019pmid:31001127
    OpenUrlPubMed
  44. ↵
    1. Reddy YNV,
    2. Obokata M,
    3. Dean PG,
    4. Melenovsky V,
    5. Nath KA,
    6. Borlaug BA
    : Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 38: 1913–1923, 2017pmid:28329100
    OpenUrlPubMed
  45. ↵
    1. Tang AS,
    2. Wells GA,
    3. Talajic M,
    4. Arnold MO,
    5. Sheldon R,
    6. Connolly S,
    7. Hohnloser SH,
    8. Nichol G,
    9. Birnie DH,
    10. Sapp JL,
    11. Yee R,
    12. Healey JS,
    13. Rouleau JL
    ; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators: Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363: 2385–2395, 2010pmid:21073365
    OpenUrlCrossRefPubMed
  46. ↵
    1. Makki N,
    2. Swaminathan PD,
    3. Hanmer J,
    4. Olshansky B
    : Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace 16: 55–62, 2014pmid:24058182
    OpenUrlCrossRefPubMed
  47. ↵
    1. Charytan DM,
    2. Patrick AR,
    3. Liu J,
    4. Setoguchi S,
    5. Herzog CA,
    6. Brookhart MA,
    7. Winkelmayer WC
    : Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 58: 409–417, 2011pmid:21664735
    OpenUrlCrossRefPubMed
  48. ↵
    1. Jukema JW,
    2. Timal RJ,
    3. Rotmans JI,
    4. Hensen LCR,
    5. Buiten MS,
    6. de Bie MK,
    7. Putter H,
    8. Zwinderman AH,
    9. van Erven L,
    10. Krol-van Straaten MJ,
    11. Hommes N,
    12. Gabreëls B,
    13. van Dorp W,
    14. van Dam B,
    15. Herzog CA,
    16. Schalij MJ,
    17. Rabelink TJ
    ; ICD2 Trial Investigators: Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients. Circulation 139: 2628–2638, 2019pmid:30882234
    OpenUrlPubMed
  49. ↵
    1. Löfman I,
    2. Szummer K,
    3. Dahlström U,
    4. Jernberg T,
    5. Lund LH
    : Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 19: 1606–1614, 2017pmid:28371075
    OpenUrlPubMed
  50. ↵
    1. Nguyen M,
    2. Rumjaun S,
    3. Lowe-Jones R,
    4. Ster IC,
    5. Rosano G,
    6. Anderson L,
    7. Banerjee D
    : Management and outcomes of heart failure patients with CKD: Experience from an inter-disciplinary clinic. ESC Heart Fail 7: 3225–3230, 2020pmid:32652822
    OpenUrlPubMed
  51. ↵
    1. Sankaranarayanan R,
    2. Douglas H,
    3. Wong C
    : Cardio-nephrology MDT meetings play an important role in the management of cardiorenal syndrome. Br J Cardiol 27: 80–82, 2020
    OpenUrl
  52. ↵
    1. Junarta J,
    2. Fernandez M,
    3. Chung I,
    4. Salha A,
    5. Klaud Francheska BD,
    6. Lowe-Jones R,
    7. Sharma R,
    8. Firoozi S,
    9. Banerjee D
    : Role of a cardio-renal multi-disciplinary team meeting in managing cardiovascular risk in patients on kidney transplant waitlists. Clin Transplant 34: e14061, 2020pmid:32780546
    OpenUrlPubMed
    1. Pfeffer MA,
    2. Braunwald E,
    3. Moyé LA,
    4. Basta L,
    5. Brown EJ Jr..,
    6. Cuddy TE,
    7. Davis BR,
    8. Geltman EM,
    9. Goldman S,
    10. Flaker GC,
    11. Klein M,
    12. Lamas GA,
    13. Packer M,
    14. Rouleau J,
    15. Rouleau JL,
    16. Rutherford J,
    17. Wertheimer JH,
    18. Hawkins CM
    : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669–677, 1992 pmid:1386652
    OpenUrlCrossRefPubMed
    1. Yusuf S,
    2. Pitt B,
    3. Davis CE,
    4. Hood WB,
    5. Cohn JN
    ; SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302, 1991pmid:2057034
    OpenUrlCrossRefPubMed
    1. Yusuf S,
    2. Pitt B,
    3. Davis CE,
    4. Hood WB Jr.,
    5. Cohn JN
    ; SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published correction appears in N Engl J Med 327: 1768, 1992]. N Engl J Med 327: 685–691, 1992pmid:1463530
    OpenUrlCrossRefPubMed
    1. Pfeffer MA,
    2. Swedberg K,
    3. Granger CB,
    4. Held P,
    5. McMurray JJ,
    6. Michelson EL,
    7. Olofsson B,
    8. Ostergren J,
    9. Yusuf S,
    10. Pocock S
    ; CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme [published correction appears in Lancet: 1744, 2009]. Lancet 362: 759–766, 2003pmid:13678868
    OpenUrlCrossRefPubMed
    1. Pitt B,
    2. Zannad F,
    3. Remme WJ,
    4. Cody R,
    5. Castaigne A,
    6. Perez A,
    7. Palensky J,
    8. Wittes J
    ; Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717, 1999pmid:10471456
    OpenUrlCrossRefPubMed
    1. Zannad F,
    2. McMurray JJ,
    3. Krum H,
    4. van Veldhuisen DJ,
    5. Swedberg K,
    6. Shi H,
    7. Vincent J,
    8. Pocock SJ,
    9. Pitt B
    ; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21, 2011pmid:21073363
    OpenUrlCrossRefPubMed
    1. Pitt B,
    2. Remme W,
    3. Zannad F,
    4. Neaton J,
    5. Martinez F,
    6. Roniker B,
    7. Bittman R,
    8. Hurley S,
    9. Kleiman J,
    10. Gatlin M
    ; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med 348: 2271, 2003]. N Engl J Med 348: 1309–1321, 2003pmid:12668699
    OpenUrlCrossRefPubMed
    1. Swedberg K,
    2. Komajda M,
    3. Böhm M,
    4. Borer JS,
    5. Ford I,
    6. Dubost-Brama A,
    7. Lerebours G,
    8. Tavazzi L
    ; SHIFT Investigators: Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study [published correction appears in Lancet 376: 1988, 2010]. Lancet 376: 875–885, 2010pmid:20801500
    OpenUrlCrossRefPubMed

If you are:

  • an ASN member, select the "ASN Member" login button. 
  • an individual subscriber, login with you User Name and Password.
  • an Institutional user, select the Institution option where you will be presented with a list of Shibboleth federations. If you do not see your federation, contact publications@asn-online.org. 

ASN MEMBER LOGIN

ASN MEMBER LOGIN

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.

Purchase access

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$34.00

In order to get access to the article, you must have an account.  If you have an account, enter your user name and password into the boxes above. If you do not have an account, follow the instructions below to create one.  Once you have purchased the article, you will have access to it for 24 hours.  

Steps for Creating an Account:

Click the "Purchase Access" button.  The page will redisplay with the following message at the top of the screen which contains the link to register for an account.

When you create an account, you will be asked for your name, email address and other information.  Just like commercial web sites, we do need details from you in order to complete your purchase of an article.  

You will then be asked to register a user name, email address and you will need to create a password that is at least eight characters in length. You do not need an ASN Member number to complete the form. As you move through the registration page, you will have to verify you are a person by completing a Captcha request.   Lastly, your first and last name will be required. 

Once your information is successfully saved, the system will redisplay the home page of the journal.  From there, navigate back to the article to purchase.  Select the article and at the bottom of the page, use the credentials you just created to login. The article will be added to your shopping cart.  You can continue to navigate across JASN and CJASN adding to your cart from both journals. When you are ready to complete your purchse, select the Shopping Cart from the upper right hand corner of the page and follow the onscreen instructions. 

PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 16 (7)
Clinical Journal of the American Society of Nephrology
Vol. 16, Issue 7
July 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Management of Heart Failure Patient with CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Management of Heart Failure Patient with CKD
Debasish Banerjee, Giuseppe Rosano, Charles A. Herzog
CJASN Jul 2021, 16 (7) 1131-1139; DOI: 10.2215/CJN.14180920

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Management of Heart Failure Patient with CKD
Debasish Banerjee, Giuseppe Rosano, Charles A. Herzog
CJASN Jul 2021, 16 (7) 1131-1139; DOI: 10.2215/CJN.14180920
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Epidemiology of CKD in Heart Failure
    • The Interdependence of the Heart and Kidney
    • AKI in Patients with Heart Failure and CKD
    • Heart Failure Therapy in Patients with CKD
    • Diuretic Therapy
    • Renin-Angiotensin-Aldosterone System Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD
    • Angiotensin Receptor and Neprilysin Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD
    • Ivabradine and β-Blocker Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD
    • Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients with Heart Failure with Reduced Ejection Fraction and CKD
    • Management of Iron Deficiency and Anemia in Patients with Heart Failure with Reduced Ejection Fraction and CKD
    • KRT
    • Device Therapy
    • Heart Failure with Preserved Ejection Fraction in Patients with CKD
    • Multidisciplinary Care
    • The Way Forward
    • Disclosures
    • Funding
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis
  • Classification of Uremic Toxins and Their Role in Kidney Failure
  • Transforming the Care of Patients with Diabetic Kidney Disease
Show more Reviews

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • chronic kidney disease
  • heart failure
  • dialysis

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire